Connect your AI

Prime Medicine PRME Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

RegenxbioRGNX

——

Sarepta Therapeutics, Inc.SRPT

——

Wave Life SciencesWVE

——

4D Molecular TherapeuticsFDMT

——

Other financials

Income statement

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Prime Medicine's accrued progress collections and price adjustments?: Prime Medicine (PRME) reported accrued progress collections and price adjustments of $57.78M in Q1 2026.
How has Prime Medicine's accrued progress collections and price adjustments changed year-over-year?: Prime Medicine's accrued progress collections and price adjustments decreased by 4.8% year-over-year, from $60.66M to $57.78M.